Vaxcyte PCVX
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
- Form
- 8-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001193125-25-067901
- Document
- 8-K
- Exhibit 99.1
- Press release
- Makes a Regulation FD disclosure (7.01)
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- PERRIGO PRGO public float $3.7B, Jun 27, 2025
- Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
- Ultragenyx Pharmaceutical RARE public float $3.4B, Jun 30, 2025
- Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
- Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
